ResMed Inc is a global leader in digital health and cloud-connected devices that serve individuals with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions. The company specializes in creating innovative solutions that improve the quality of life for patients through advanced technology, including ventilators, sleep therapy devices, and patient monitoring systems. By leveraging data analytics and machine learning, ResMed enhances patient engagement and treatment adherence, thereby promoting better health outcomes. The company's commitment to research and development allows it to continuously advance its portfolio, making a significant impact on the healthcare landscape. Read More
Minneapolis, MN – October 13, 2025 – Inspire Medical Systems (NYSE: INSP) emerged as a standout performer in today's trading session, witnessing its stock price jump by an impressive 3.9% by the closing bell. This significant surge is primarily attributed to the overwhelmingly positive clinical outcomes data presented for its next-generation
A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments.
Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.
Learn how ResMed (RMD) exemplifies a strong dividend stock with a 10+ year growth streak, a low payout ratio, and robust profitability for reliable passive income.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at approximately 1:20 p.m. (British Summer Time) in London.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at patient monitoring stocks, starting with ResMed (NYSE:RMD).
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.
ResMed (RMD) is a top dividend stock with a low payout ratio, strong financial health, and consistent growth, ensuring sustainable income for investors.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
ResMed has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.9%. The stock now trades at $281.96, marking a 20.7% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.
Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care
Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
